Immunotherapy for advanced renal cell cancer. (Q30887373)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Immunotherapy for advanced renal cell cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

1 reference

Europe PubMed Central

retracted paper

1 reference

Retraction Watch

29 December 2023

https://doi.org/10.1002/14651858.CD001425.pub3

http://retractionwatch.com/2010/09/20/progressive-how-the-cochrane-library-handles-updates-in-progress/

Immunotherapy for advanced renal cell cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

1 reference

based on heuristic

inferred from title

author name string

C Coppin

1

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

F Porzsolt

2

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

J Kumpf

3

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

A Coldman

4

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

T Wilt

5

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

publication date

1 January 2000

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Cochrane Database of Systematic Reviews

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

CD001425

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Biological and clinical effects of interferon-beta ser at two doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Interferon therapy in disseminated renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Treatment of Metastatic Renal Cell Carcinoma With Nephrectomy, Interleukin-2 and Cytokine-Primed or CD8(+) Selected Tumor Infiltrating Lymphocytes from Primary Tumor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Randomized Study of Interleukin 2 (IL-2) Alone vs IL-2 Plus Lymphokine-Activated Killer Cells for Treatment of Melanoma and Renal Cell Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

[Advantages and problems of multicenter therapy studies exemplified by a study of the treatment of metastasizing renal cell carcinoma with recombinant interferon-alpha-2c].

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Is there logic in the placebo?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Are cytokine responses in renal cell cancer the product of placebo effect of treatment or true biotherapy? What trials are needed now?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Immunotherapy: the last 25 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Fair conduct and fair reporting of clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

Many reports of RCTs give insufficient data for Cochrane reviewers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001425

21 January 2018

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Recombinant interferon-alpha 2 antibodies in renal cell carcinoma. Delta-P Study Group

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Immunotherapy of metastatic renal cell cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

[Treatment of metastatic kidney cancer with recombinant alpha-2 or gamma interferon. Results of 2 clinical phase II and III studies]

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneo

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Randomised study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

A Prospective Randomized Evaluation of the Prophylactic Use of Low-Dose Dopamine in Cancer Patients Receiving Interleukin-2

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD001425

Identifiers

10.1002/14651858.CD001425

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30887373&oldid=2074337116"